The World Hypertension League (WHL) is pleased to announce the next World Hypertension Congress, scheduled to take place in Goiânia, Brazil, from May 13 -15, 2027. We invite colleagues from Latin America and all other regions of the world to share suggestions for topics to be addressed during this important global event. You are also encouraged to contribute to the success of the Congress by submitting abstracts presenting your original research and by considering attending in person what we aim to make a high-level scientific meeting of global relevance. 

The World Hypertension League is proud to present an overview video featuring Prof. Gianfranco Parati, MD. 

Read more …

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension.

Read more …

Dear Colleagues,

Greetings from New Orleans. I have had a busy but very pleasant summer of travel to Italy, Croatia, Slovenia and South Africa. Thanks to many colleagues who made the “journey” so delightful. As you may already know, we had to change the dates of our World Hypertension Congress to March 7-9, 2025. Nothing has changed except the dates. I am delighted that Dr. Thomas Frieden, President and CEO of Resolve to Save Lives (RTSL) and former Director of the US Centers for Disease Control and Prevention will deliver an address during the opening ceremony.

Read more …

Dear Colleagues,

In this issue of the Newsletter, I want to comment on the “state of play” for high blood pressure (BP) treatment and control around the world. Obviously, we’ve made tremendous progress since diuretics were introduced as the first effective drugs for treatment of hypertension in the 1950s. Since then, efficacy trials have demonstrated the most effective nonpharmacological interventions for prevention and treatment of hypertension (weight loss, dietary sodium reduction and potassium supplementation, consumption of a heart healthy diet, physical activity, and abstinence or moderation in alcohol intake) as well as the efficacy of low-dose pharmacotherapy for prevention of hypertension and more intensive pharmacotherapy for treatment of high BP and prevention of cardiovascular disease (CVD).

Read more …

Background 

Hypertension (high blood pressure) is among the leading risk factors for cardiovascular disease, stroke, and kidney failure, and is directly associated with more than 10 million annual deaths globally.^1,2 Hypertension is often referred to as a “silent killer,” since people with hypertension typically do not display symptoms.²

Read more …